JP2006502195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502195A5 JP2006502195A5 JP2004538994A JP2004538994A JP2006502195A5 JP 2006502195 A5 JP2006502195 A5 JP 2006502195A5 JP 2004538994 A JP2004538994 A JP 2004538994A JP 2004538994 A JP2004538994 A JP 2004538994A JP 2006502195 A5 JP2006502195 A5 JP 2006502195A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridylmethyl
- vitamin
- formula
- compound
- phthalazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 6
- WHOWNXIYXLWMGJ-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)phthalazine Chemical class N=1N=CC2=CC=CC=C2C=1CC1=CC=NC=C1 WHOWNXIYXLWMGJ-UHFFFAOYSA-N 0.000 claims 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- -1 cyano, carboxy Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 241000534944 Thia Species 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 2
- 229960002594 arsenic trioxide Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 229960003284 iron Drugs 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 2
- 229950000578 vatalanib Drugs 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 235000019158 vitamin B6 Nutrition 0.000 claims 2
- 239000011726 vitamin B6 Substances 0.000 claims 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 2
- 235000005282 vitamin D3 Nutrition 0.000 claims 2
- 239000011647 vitamin D3 Substances 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 229940011671 vitamin b6 Drugs 0.000 claims 2
- 229940021056 vitamin d3 Drugs 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000011254 conventional chemotherapy Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41317602P | 2002-09-24 | 2002-09-24 | |
| PCT/EP2003/010578 WO2004028542A1 (en) | 2002-09-24 | 2003-09-23 | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502195A JP2006502195A (ja) | 2006-01-19 |
| JP2006502195A5 true JP2006502195A5 (https=) | 2006-11-09 |
Family
ID=32043216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004538994A Pending JP2006502195A (ja) | 2002-09-24 | 2003-09-23 | 骨髄異形成症候群の処置用医薬の製造のための４−ピリジルメチル−フタラジン誘導体の使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20060128716A1 (https=) |
| EP (1) | EP1545534B1 (https=) |
| JP (1) | JP2006502195A (https=) |
| KR (1) | KR20050074450A (https=) |
| CN (1) | CN100372535C (https=) |
| AT (1) | ATE359789T1 (https=) |
| AU (1) | AU2003299065B2 (https=) |
| BR (1) | BR0314647A (https=) |
| CA (1) | CA2499738A1 (https=) |
| CR (1) | CR7754A (https=) |
| DE (1) | DE60313344T2 (https=) |
| EC (1) | ECSP055700A (https=) |
| ES (1) | ES2285251T3 (https=) |
| HR (1) | HRP20050281A2 (https=) |
| MX (1) | MXPA05003161A (https=) |
| NO (1) | NO20051936L (https=) |
| PL (1) | PL374696A1 (https=) |
| PT (1) | PT1545534E (https=) |
| RS (1) | RS20050228A (https=) |
| RU (1) | RU2353364C2 (https=) |
| WO (1) | WO2004028542A1 (https=) |
| ZA (1) | ZA200502212B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001519366A (ja) * | 1997-10-15 | 2001-10-23 | ポーラクス バイオファーマシュティカルズ，インコーポレーテッド | ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法 |
| EP1922311A2 (en) | 2005-09-09 | 2008-05-21 | Brystol-Myers Squibb Company | Acyclic ikur inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| RU2136308C1 (ru) * | 1994-11-16 | 1999-09-10 | Жемчугов Владислав Евгеньевич | Стимулятор роста костно-мозговых клеток человека |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| WO2000059509A1 (en) * | 1999-03-30 | 2000-10-12 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| JP5027369B2 (ja) * | 1999-12-06 | 2012-09-19 | ガイストリッヒ ファーマ アーゲー | 腫瘍を治療する方法 |
-
2003
- 2003-09-23 HR HR20050281A patent/HRP20050281A2/xx not_active Application Discontinuation
- 2003-09-23 KR KR1020057004971A patent/KR20050074450A/ko not_active Ceased
- 2003-09-23 CA CA002499738A patent/CA2499738A1/en not_active Abandoned
- 2003-09-23 DE DE60313344T patent/DE60313344T2/de not_active Expired - Lifetime
- 2003-09-23 RS YUP-2005/0228A patent/RS20050228A/sr unknown
- 2003-09-23 US US10/528,914 patent/US20060128716A1/en not_active Abandoned
- 2003-09-23 EP EP03798175A patent/EP1545534B1/en not_active Expired - Lifetime
- 2003-09-23 RU RU2005112711/14A patent/RU2353364C2/ru not_active IP Right Cessation
- 2003-09-23 PT PT03798175T patent/PT1545534E/pt unknown
- 2003-09-23 CN CNB038227118A patent/CN100372535C/zh not_active Expired - Fee Related
- 2003-09-23 AU AU2003299065A patent/AU2003299065B2/en not_active Ceased
- 2003-09-23 JP JP2004538994A patent/JP2006502195A/ja active Pending
- 2003-09-23 PL PL03374696A patent/PL374696A1/xx not_active Application Discontinuation
- 2003-09-23 WO PCT/EP2003/010578 patent/WO2004028542A1/en not_active Ceased
- 2003-09-23 ES ES03798175T patent/ES2285251T3/es not_active Expired - Lifetime
- 2003-09-23 AT AT03798175T patent/ATE359789T1/de not_active IP Right Cessation
- 2003-09-23 MX MXPA05003161A patent/MXPA05003161A/es active IP Right Grant
- 2003-09-23 BR BR0314647-2A patent/BR0314647A/pt not_active IP Right Cessation
-
2005
- 2005-03-16 ZA ZA200502212A patent/ZA200502212B/en unknown
- 2005-03-17 CR CR7754A patent/CR7754A/es not_active Application Discontinuation
- 2005-03-23 EC EC2005005700A patent/ECSP055700A/es unknown
- 2005-04-20 NO NO20051936A patent/NO20051936L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533748A5 (https=) | ||
| EP0622076B1 (en) | Inhibitor for restenosis after percutaneous coronary arterioplasty | |
| JP2001518517A5 (https=) | ||
| JPWO2020163823A5 (https=) | ||
| RU2375058C2 (ru) | Комбинации, включающие эпотилоны, и их фармацевтическое применение | |
| JP2005501825A5 (https=) | ||
| AU2002328921A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| JP2006502195A5 (https=) | ||
| US6881751B2 (en) | Medicament containing platinum complex compounds and the use thereof | |
| EP1545534B1 (en) | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes | |
| AU2002251763B2 (en) | Method for treating cancer | |
| JP2003535874A (ja) | 置換アクリロイルジスタマイシン誘導体、タキサン類及び／又は代謝拮抗剤を含む腫瘍に対する併用療法 | |
| JP2006503874A5 (https=) | ||
| JP2002518467A5 (https=) | ||
| JP2006507319A5 (https=) | ||
| JP2006503874A (ja) | Ａｍｍの処置 | |
| AU2008203233A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| WO2004056367A1 (en) | Treatment of von hippel lindau disease | |
| WO2006105317A2 (en) | Antitumorigemic drug combination comprising a vegf-inhibitor and a thrombospondin-1 peptidomimetic |